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1. Introduction
   While irritable bowel syndrome (IBS) is common in the 
West, early studies suggest that the prevalence of IBS is 
low in developing countries. However, recent studies point 
out that there was increasing prevalence of IBS in newly 
developing Asian countries. Together with the changes with 
evolution of Asian countries such as westernization of the 
diet and increased psychosocial stress, it is proposed that 
loss of internal protective effect, could 
give rise to a more uniform worldwide prevalence of IBS. 
IBS is one of the commonest gastrointestinal disorders. 
It is worrisome chronic disease of very productive life 
posing serious burden to medical care costs. The quality 
of life also suffers serious beating from IBS[1,2]. Varying 
systemic involvement of the gastrointestinal tract and 
both peripheral and central nervous system makes the 
syndrome difficult to be improved with single therapeutic 
agent[3,4]. Visceral hypersensitivity is highly prevalent in 
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Objective: To develop agents that are specifically effective in controlling the key disturbance of 
visceral hyperalgesia besides abating of associated multiple symptoms, and evaluate comparative 
effectiveness for IBS symptom relief for standard regimen (antispasmodic and probiotic) and add-
on amitriptyine or riluzole regimens following two weeks administration.
Methods: 108 patients with visceral hypersensitivity accompanying IBS, divided into three 
groups were studied. First group received standard treatment (mebeverine 200 mg twice daily and 
probiotic 200 mg twice daily). Second group received add-on amitriptyline 25 mg before bedtime, 
while the third group got add-on riluzole 50 mg twice daily. Overall gastrointestinal symptom 
rating scale improving symptoms and hospital anxiety depression scale improving associated 
psychological morbidity were employed as measures at induction and at two-week follow-up 
period. Individual symptom scores were also examined to define the outcome profiles.
Results: Riluzole regimen resulted in significant reduction of overall gastrointestinal symptom 
rating scale score, not the other two regimens. Pain relief was seen with both riluzole and 
amitriptyline regimens significantly superior to standard treatment regimen, but riluzole effect 
appeared specific and independent anxiolytic effect. Amitriptyline caused relief in diarrhea and 
did not benefit in constipation point to non-specific remedial role in IBS.
Conclusions: Riluzole specifically relieves visceral hypersensitivity and is proved to be superior 
to current treatments in IBS patients. It appears a lead remedy based on glutamate transporter 
mechanisms in visceral hypersensititvity.
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all functional bowel disorders with wider somatic referral of 
symptoms. Hypersensitivity at the level of the dorsal horn 
of the spinal cord is induced by peripheral inflammation 
or injury in the brain-gut axis. This process is mediated 
by mutual stimulation of N-methyl-d-aspartate receptors 
and neurokinin 1 receptors[5]. Tricyclic antidepressants 
(amitriptyline) have been used with variable success in 
control of IBS symptoms[6]. They cause sodium channel block 
in nociceptive neurons in an use-dependent manner. The 
antispasmodic compound mebeverine, a methoxybenzamine 
derivative is also widely used in IBS management[7]. It is 
thought to decrease motility and intraluminal bowel pressure 
via a direct effect on smooth muscle cells[8]. Probiotics 
also have shown some potential for global relief of IBS 
symptoms[9].               
   Neurotransmitter antagonist to reduce visceral 
hypersensitivity is an exciting new era for the treatment 
of functional gastrointestinal disorders[10]. The n-methyl 
d-aspartate (NMDA) receptor appears to be the most important 
molecular factor in the development of central sensitization 
at the spinal dorsal horn[11]. Changes in expression and 
glutamate uptake activity of spinal glutamate transporter 
are suspected to play a critical role in both induction and 
maintenance of hyperalgesic state by regulation of regional 
glutamate homeostasis. Human pharmacological studies 
have demonstrated that antagonism of the NMDA receptor 
preventing the development of central sensitisation within 
the oesophagus and ketamine may even reverse established 
visceral hypersensitivity[12]. Riluzole (a glutamate reuptake 
enhancer and NMDA receptor antagonist) was reported 
to attenuate hyperalgesia in neuropathic pain models at 
doses devoid of side effects, an action chiefly connected to 
the activation in glutamate reuptake[13]. The inclusion of 
riluzole in therapeutic regimen excluding amitriptyline is 
herein assessed for comparative effectiveness in relieving 
symptoms and improving quality of life in patients of IBS.
2. Materials and methods
2.1. Patients 
   After prior approval of institutional ethics committee, 
IBS patients aged 18 years or older with symptoms that 
fulfilled the Rome II criteria[14] for IBS for at least 6 months 
were included in the study. History, physical examinations 
(including sigmoidoscopy/colonoscopy), routine and special 
laboratory investigations were recorded. Patients were 
excluded if they were lactose intolerant or had any other 
significant medical condition requiring concurrent therapy. 
Cases with psychiatric disorder or substance abuse within 
the previous 2 years, pregnant or breast-feeding women and 
those using hormonal contraception were also excluded. All 
included cases were advised to observe week long drug free 
period prior to inclusion in the study.
2.2. Study design
   Strictly in sequence, cases entering the study were 
prescribed A, B or C therapy regimens. Regimen A: 
mebeverine 200 mg twice daily and probiotic 200 mg twice 
daily; Regimen B: Regimen A+amytriptyline 25 mg before 
bedtime; Regimen C: Regimen A+riluzole 50 mg twice daily.
2.3. Clinical scales 
   Standard gastrointestinal symptom rating scale (GSRS)[15] 
was used as measure. Concurrent psychological morbidity 
was assessed using hospital anxiety depression scale (HADS)
[16]. The scores were compared at induction and at 2 weeks 
of compliant adherence to the prescribed therapy. Non-
compliance with the prescribed regimen was thoroughly 
enquired and cases with more than one occasion of missing 
medicine were excluded.  
2.4. Statistical methods 
   Overall variance of outcomes relating different symptoms 
in the compared regimens was examined using Kruskal-
Wallis ANOVA test[17]. Chi square statistic was employed 
to evaluate relative outcomes of symptom relief in the 
compared treatment groups. P value less than 0.05 was 
considered significant. Interrelation among different 
symptoms was analysed using Spearman’s correlation 
coefficient (ρ)[18]. SPSS version 17 software was used.
3. Results
   Table 1 summarizes GSRS scores prevalent among the 
overall studied sample of IBS patients. Pain was constantly 
present in all cases. Indigestion also occurred in majority, 
Table 1
Overall profile of GSRS scores.
Number of 
cases
GSRS score
Std. deviation Variance
Mean
Range Min. Max. Statistic Std. error
Reflux 55 5 1 6 1.292 1.669 3.67 0.174
Pain 108 8 1 9 2.278 5.189 4.77 0.219
Indigestion 63 10 1 11 2.537 6.437 5.83 0.320
Diarrhoea 71 6 2 8 1.647 2.714 4.17 0.196
Constipation 19 6 2 8 1.968 3.871 4.74 0.451
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the score varied quite. Diarrhoea and constipation were 
prevalent next in order and their magnitude had less 
variance. Reflux occurred in nearly half of the cases with 
clearly narrow variation of magnitude.
   Table 2 summarizes HADS scores among the studied 
sample of IBS cases in general. Nearly half the cases suffered 
anxiety and slightly less had depression while a third (29) 
had significant presence of both the symptoms. It appears 
that these psychiatric co-morbidities have far varied 
contributions among IBS patients.
   Overall improvement in particular symptoms following 
various treatment regimens was assessed for variance. 
Pain and diarrhea scores as well as overall GSRS scores 
significantly differed among the treatment groups. 
Significant differences were seen in outcomes of studied 
three regimens in respect to pain relief, diarrhea and overall 
GSRS scores. (Table 3 and Figure 1)
Table 3
Post-treatment changes in symptom scores in various groups (Kruskal-
Wallis ANOVA test).
Treatment groups ANOVA analysis
A B C P value
Reflux
> Median 4 4 5
0.894
≤ Median 13 14 15
Pain
> Median 7 20 24
0.000
≤ Median 25 15 17
Indigestion
> Median 7 6 6
0.903
≤ Median 13 14 17
Diarrhoea
> Median 4 14 15
0.009
≤ Median 15 10 13
Constipation
> Median 1 1 0
0.763
≤ Median 6 4 7
GSRS total
> Median 8 16 19
0.000
≤ Median 24 19 22
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Figure 1. Box-plots of overall GSRS scores pre and post treatment 
with median marks in various study groups.  
 
   Reflux symptoms were not improved significantly by any 
of the regimens, yet the outcomes were numerically better 
with riluzole. Both amitriptyline (P=0.0539) and riluzole 
(P=0.0352) regimens gave significant pain relief wherein 
outcomes with riluzole had superior level of statistical 
significance. Overall GSRS scores improved significantly 
solely in the riluzole treatment group (P=0.0201). As a 
contrast, only amitriptyline regimen caused significant 
relief in diarrhea (P=0.0305) and did not benefit in 
constipation. Riluzole did insignificantly reduce diarrhea 
better than the standard regimen A (Table 4).
   Pain is significantly associated with degree of anxiety 
(P<0.0001). Riluzole as well as amitriptyline regimens 
simultaneously relieved pain and anxiety. Another 
symptom diarrhea, also correlated to anxiety (P<0.0001), 
Table 2
Overall profile of HADS scores.
No. of cases HADS Score
Std. deviation Variance
Mean
Total HADS≥8 Range Min. Max. Statistic Std. error
Anxiety 108 53 18 0 18 5.482 30.055 8.40 0.528
Depression 108 46 19 0 19 5.148 26.502 7.61 0.495
Table 4
Distribution of symptom severity among various treatment groups (comparison of before and after treatment).        
Treatment groups
A B C
Pre Post P Pre Post P Pre Post P
Reflux > Median 6 5 1 4 3 1 5 3 0.6948
≤ Median 11 12 14 15 15 17
Pain > Median 10 14 0.4390 13 5 0.0539 19 9 0.0352
≤ Median 22 18 22 30 22 32
Indigestion > Median 11 11 1 6 6 1 8 15 1
≤ Median 9 9 14 14 15 16
Diarrhoea > Median 5 4 1 12 4 0.0305 11 6 0.2448
≤ Median 14 15 12 20 17 22
Constipation > Median 3 2 1 3 3 1 3 3 1
≤ Median 4 5 2 2 4 4
GSRS total > Median 15 16 1 17 11 0.2223 20 9 0.0201
≤ Median 17 16 18 24 21 32
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but significant improvement of diarrhea was seen 
selectively with amitriptyline (P=0.003), not so much with 
riluzole. Despite correlation of depression to constipation 
(P<0.0001), amitriptyline did not relieve constipation 
significantly (Table 5, Figure 2 and 3). 
Figure 2. Box-plots of anxiety scores pre and post treatment with 
median marks in various compared groups.     
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Figure 3. Box-plots of depression scores pre and post treatment with 
median marks in various compared groups. 
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   Table 6 shows that higher pain relief appears to occur 
more frequently in cases with higher anxiety scores and 
those with lesser anxiety frequently continued to get 
inferior pain relief. Such difference is significant both in 
standard therapy (P=0.0695)  and riluzole regimen (P=0.0283) 
but not in amitriptyline regimen (P=0.2075). This would 
suggest that the pain relieving effect of riluzole is more 
Table 5
Spearman’s correlation (氀)  between symptoms with one-another  (values indicate P )
Reflux Pain Indgs Diarr Const GSRS Anx Depress
Spearman's 
rho (氀)
Reflux
Correlation Coefficient   1.000 -0.090 -0.250 0.032 -0.047 0.025 -0.040   0.149
Sig. (2-tailed)   0.512   0.098 0.872   0.896 0.854   0.771   0.278
Pain
Correlation Coefficient -0.090   1.000   0.190    0.668**   0.034    0.730**     0.650** -0.124
Sig. (2-tailed)   0.512   0.136 0.000   0.890 0.000   0.000   0.200
Indigestion
Correlation Coefficient -0.250   0.190   1.000 0.274   0.149    0.766**   0.197    0.261*
Sig. (2-tailed)   0.098   0.136 0.143   0.596 0.000   0.121   0.039
Diarrhoea
Correlation Coefficient   0.032     0.668**   0.274 1.000    0.667**     0.540** -0.085
Sig. (2-tailed)   0.872   0.000   0.143 0.000   0.000   0.480
Constipation
Correlation Coefficient -0.047   0.034   0.149   1.000    0.849**   0.156     0.915**
Sig. (2-tailed)   0.896   0.890   0.596 0.000   0.523   0.000
GSRS
Correlation Coefficient   0.025     0.730**     0.766**   0.667**     0.849** 1.000     0.510**   0.184
Sig. (2-tailed)   0.854   0.000   0.000 0.000   0.000   0.000   0.056
Anxiety
Correlation Coefficient -0.040     0.650**   0.197   0.540**   0.156    0.510**   1.000   0.018
Sig. (2-tailed)   0.771   0.000   0.121 0.000   0.523 0.000   0.854
Depression
Correlation Coefficient   0.149 -0.124    0.261*   -0.085      0.915** 0.184   0.018   1.000
Sig. (2-tailed)   0.278   0.200   0.039  0.480   0.000 0.056   0.854
**
Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).
Table 6
Pain relief with respect to basal anxiety scores with different treatment regimens.
Pre-treatment anxiety score
Standard group (A) P 
value
Amitriptyline group (B) P 
value
Riluzole group (C) P 
valueAbove median Below median Above median Below median Above median Below median
Post-treatment 
pain relief
Above median 9 3 0.0695 5 2 0.2075 7 2 0.0283
Below median 7 13 11 17 11 21
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specific and less dependent on anxiolytic mechanism.
   
4. Discussion
   Understanding of pain and its receptors is based 
on studies of somatic sensory system which leaves 
much regarding unique features of visceral pain[19]. 
Visceral pain therefore is managed rather poorly and 
drugs relieving somatic pain inflict adverse visceral 
effects. Pathophysiology of chronic visceral pain is 
beginning to be understood with focus on alterations in 
the peripheral and central nervous system. A number 
of receptors, neurotransmitters, cytokines and second 
messenger systems in the neurons are implicated in 
visceral hypersensitivity. NMDA receptors are found in 
the peripheral nervous system as well as central terminal 
of affected neurons and play important role in regulating 
release of nociceptive neurotransmitters[20]. Since visceral 
hypersensitivity in IBS typically exhibits spontaneous 
periods of flare and remissions, clinical evaluation of 
candidate remedies is difficult. It therefore becomes 
relevant to study results as function of subgroups based on 
clinical symptoms, with tendency to benefit with particular 
therapeutic approach.
   Modulation of visceral nociceptive pathway can occur 
at peripheral, spinal and supraspinal sites[21]. Therefore 
compounds which hit several targets should offer superior 
therapeutic option. Glutamate is the major excitatory 
neurotransmitter and mediates visceral nociceptive 
neurotransmission and hypersensitivity. Removal of 
extracellular glutamate is predominantly mediated by glial 
glutamate transporter-1. The pharmacological approach 
to up-regulate glutamate transporter-1 with ceftriaxone 
has been successful in mitigating visceral nociception[22]. 
Riluzole is a positive regulator of glutamate transporter 
activity and has shown to attenuate neuropathic pain 
behaviors, indicating that changes in expression and 
uptake activity of spinal glutamate transporters may play a 
critical role in induction and maintenance of neuropathic 
pain[23]. This makes it a lead to explore development of 
specific therapy for visceral hypersensitivity in IBS[24].
   Most significant finding of the study is that adopting 
the standard GSRS score, both riluzole and amitriptyline 
regimens, not the standard regimen, resulted in significant 
improvement. Riluzole regimen distinctly renders 
significant relief of pain symptoms suffered by IBS 
cases, at least comparable to those given amitriptyline 
medication. The relief of anxiety does not appear to 
significantly contribute to pain relief produced by 
riluzole, which makes it more specific medication for 
IBS than the antidepressants. Anti-diarrheal benefit of 
amitriptyline may be consequent to anti-cholinergic 
effects. Amitriptyline does not relieve constipation 
despite association of constipation to depression. Both 
these findings make amitriptyline as nonspecific drug for 
treating IBS. The development of visceral hyperalgesia 
involves alterations at transcriptional level caused by 
variety of stresses including some hazardous to very 
survival of the neurons. Riluzole and other benzothiazoles 
protect against transcriptional impact and adverse 
molecular networks following neuronal stress[25]. Suitability 
of riluzole for symptom relief as well as potential for 
prevention of neurodegenerative consequences associating 
visceral hypersensitivity do provide a new class of specific 
therapeutic agent for treating irritable bowel syndrome.
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Comments 
Background
   The last decade has seen a tremendous surge of interest 
in the study of the augmented visceral sensitivity of the 
gut in several disease states. For further advance of this 
discipline, novel diagnostic tests and treatments are 
necessary but these await a clearer understanding of the 
mechanisms and pathophysiology of visceral sensation, 
with particular emphasis on effects of medications on 
antinociception. Riluzole is one such excellent candidate 
which needs to be evaluated.
  
Research frontiers
   A prerequisite for correction of visceral hypersensitivity 
in IBS is a more thorough understanding of the transmitters 
or mediators involved in visceral hypersensitivity and the 
development of novel, selective approaches to target those 
transmitters. Preclinical data on role of riluzole in IBS is 
encouraging and clinical studies on this front are welcome.
Related reports
   GSRS and HADS are valid and effective measures to 
evaluate their respective parameters. Statistical measures 
used here are appropriate and adequate.
Innovations and breakthroughs
   Very few studies regarding role of riluzole are published. 
Little data, whatever available, is mostly pre-clinical 
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only. This study is a commendable effort to evaluate the 
encouraging results obtained in preclinical studies in a 
clinical form. More such studies targeting brain-gut axis 
should be encouraged. 
  
Applications
   Riluzole is not only glutamate reuptake enhancer but 
also NMDA receptor antagonist. It can act in many ways in 
the central axis to counter the visceral pain. This study 
can be used as a reference study and studies of this type 
need to be encouraged on a larger patient population to 
get better inference for riluzole.    
Peer review
   This is a prudent study which meticulously evaluates 
the action of riluzole on brain-gut axis in abating visceral 
hypersensitivity, using valid clinical scales and adequate 
statistical measures. Results are encouraging and exciting, 
and may act as a lead to future therapies.
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